John Muir Dr

Davis Ct

Larkin and Ellis

Alamo square

ROSG $3.98 Long

 

 

 

 

Abenomics

http://finance.yahoo.com/blogs/the-exchange/road-japanese-debt-crisis-164423450.html?l=1

FNMA 5.15 - No End In Sight

3 Min Chart

 

 

CRM 41.80

JBL 19.70

Don't wanna miss the breakout higher.  Look to buy around 19.75

 

 

 

 

ANF 49.14 -0.88

Closed -0.88, on a day the market was very strong.  DOW was +200 this morning and closed at +106.29.  ANF closed around the 61.8% retracement set from Friday.

 

ENOC 14.50 -3.34

Downgrade, broke thru upward trend.

 

SHLD 49.07

Looking to Short

 

ANF Short $50.70

Target: $45.00

 

 

ANF $50.02

My plan is to take it short starting tomorrow.

 

News Feed

http://seekingalpha.com/currents/all

BBY $26.03

Remember all the chatter was about Best Buy closing down.  Nice bounce.

 

UNXL $24.01

10 Day

 

Cowen & Co.’s Rob Stone this morning reiterates an Outperform rating on shares of touch sensor technology maker Uni-Pixel (UNXL), writing that the 26% plunge in the shares Friday was “significantly overdone,” prompted, he thinks, by a product delay that doesn’t change the company’s fundamental advantages.

 

VVUS $14.82

Is it gonna continue higher?

 

Grove and baker

VVUS

Sold at 13.93, missed the intraday high of 15.36

5 days of green bars leads me to think it'll sell-off a bit then retest highs.

News coming out has been good, break above 15.50 and im buying

Steiner and Hayes

Richmond

FNMA $2.09 - time to short?

VVUS $14.50 Daily Chart

Now if I wasn't already long this position.  Judging by the daily it is a breakout, and in these instances you buy.  Its just hard when you see 15.00 one minute, and 10 minutes later its at 14.50.

 

FEAR AND GREED

FEAR AND GREED

 

VVUS $14.50 - Rallied thru resistance

Looking at the chart yesterday, I was anticipating a big move and luckily it was to the upside.  Why the big movement?  Not really sure, not able to find much news.

 

- First Manhattan Company (FMC) added some heavyweight muscle on Thursday to its bid to shake up the board of drugmaker Vivus Inc(VVUS) by naming former Carl Icahn top lieutenant Alex Denner and two others to its slate of proposed nominees.

Vivus (VVUS) shares rose as much as 11 percent after First Manhattan, which has nearly a 10 percent stake in Vivus(VVUS), expanded its slate of proposed directors from six to nine, including Denner.

Denner, chief investment officer Sarissa Capital Management, has served on boards of biotechnology and other healthcare companies such as Biogen Idec(BIIB) and ImClone Systems, later bought by Eli Lilly and Co. Denner also is a founding partner of Sarissa, which owns about 2 percent of outstanding Vivus(VVUS) shares. Jumping into the Vivus(VVUS) proxy fight is one of his first public forays since starting his own fund.

"In every area that needs to be fixed we want to attract the highest quality human capital," Sam Colin, senior managing director at FMC and a board nominee, said in a telephone interview.

The other two nominees added to the FMC slate are Rolf Bass, who has an extensive European pharmaceutical regulatory background, and Mel Keating, who has expertise in corporate turnarounds.

Asked about the choice of Denner, Colin said, "What we wanted first and foremost was someone with Alex's track record."

"There is no one else like Alex Denner. He's not only incredibly intelligent, incredibly experienced, very thoughtful, he's easy to get along with and very helpful in contentious situations where people's emotions can get the better of them," Colin said.

Denner had been head of healthcare investments for billionaire investor Icahn, and a regular on many of Icahn's proposed director slates.

FMC, in a statement, called its slate of nominees a "clearly superior alternative to Vivus'(VVUS) current board of directors," adding that its nominees offer independence from management.

It has been agitating for change at Vivus(VVUS) since March over the company's disappointing handling of the launch of its diet drug Qsymia, which won U.S. approval in September. Even with Thursday's share gains, Vivus'(VVUS) stock is worth half of what it was last July.

Another top investor, QVT Financial LP, had previously publicly said that Vivus(VVUS) should be sold. Analysts and other investors have been calling on Vivus(VVUS) to find a pharmaceutical company partner with deep pockets and a large sales force to help get Qsymia off the ground.

Vivus (VVUS) reported Qsymia sales of only about $4 million in the first quarter.

"They've got the right asset and the fix is having the right people behind the asset," Colin said of Qsymia. "It should be a huge drug."

Vivus' (VVUS) board of directors is scheduled to be chosen at its annual shareholders meeting on July 15. Its shares closed up 7.2 percent at $14.50 and had climbed as high as $15.04 earlier

 

VVUS $13.52 - Very Important Day Today

If tomorrow VVUS is able to make another green bar, and start tapping the 14's we may see it really bust out.  Lots of resistance around 14, massive congestion area and every time it makes a run for 14 it gets denied.  Considering the way the market reversed today, tomorrow doesn't look promising, but the chart looks like its ready to spring into action.

 

VVUS $12.98

Trying to get over the hump at $13.00.  Had some negative news to the stock last week resulting in the drop.  Is it really bad news?  or just a reason to take profits.

 

VIVUS Announces Pricing of Offering of $220 Million of 4.50% Convertible Senior Notes

 

Dow Jones 15,335.28

Is the DOW getting top heavy or just gonna keep on grinding higher.  I'm just waiting for a cross-over.

 

Jackson and Taylor

Jackson st

Bush and taylor

Clay and Franklin

Ofarrell and Franklin

California and Lyon

Japantown

Sacramento st

Sai jai at Larkin/ofarrel

One of the better Thai restaurants in the tenderloin

Broderick/lombard

HDGE 16.19

2 Green, 12 Red Bars in last 14 days.

AFFY 1.27

Shares of beaten down biotech concern Affymax(AFFY) have rallied 48%, trading at $1.18, up from near their 52-week bottom of $0.78, apparently related to a SeekingAlpha article published today which cited the company as a good potential turnaround play.

AFFY has a day range of $0.80 - $1.30, with a 52-week top of $27.74.

Price: 1.18, Change: +0.38, Percent Change: +47.50

 

Short Float 42.51%

 

 

1 Month 30 Min